​

Immunome Stock (NASDAQ:IMNM)

ForecastRevenueOwnershipFinancialsChart
Immunome by TradingView

Previous Close

$25.82

52W Range

$5.15 - $26.36

50D Avg

$20.27

200D Avg

$12.83

Market Cap

$2.37B

Avg Vol (3M)

$2.13M

Beta

2.23

Div Yield

-

IMNM Company Profile

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

131

IPO Date

Oct 02, 2020

Website

IMNM Performance

IMNM Financial Summary

Dec 24Dec 23Dec 22
Revenue$9.04M$14.02M-
Operating Income$-305.80M$-109.53M$-36.90M
Net Income$-292.96M$-106.81M$-37.51M
EBITDA$-151.35M$-28.27M$-36.27M
Basic EPS$-5.00$-5.38$-3.09
Diluted EPS$-5.00$-5.38$-3.09

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
PHVSPharvaris N.V.
MAZEMaze Therapeutics, Inc.
UPBUpstream Bio, Inc.
SYRESpyre Therapeutics, Inc.
ABCLAbCellera Biologics Inc.
BHVNBiohaven Ltd.
CLDXCelldex Therapeutics, Inc.
NTLAIntellia Therapeutics, Inc.
VERAVera Therapeutics, Inc.
ZBIOZenas BioPharma, Inc.